Cellectis (CLLS) Exits Two CAR-T Programs. Can Gene Editing Justify the Clinical Reset?
Cellectis S.A. (NASDAQ:CLLS) announced on September 14 that its board approved a strategic transformation on September 11.
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Long Focus Capital Management John B. Helmers | 2,741,853 | $8,225,559 | -1% | 0.21% |
| 2. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 0 | $0 | 0% |